FARGO, N.D., Oct. 24, 2017 /PRNewswire/ -- Aldevron, a global provider of plasmid DNA and gene editing enzymes used to support novel cancer therapies, will be a Platinum sponsor of the 2017 Believe Ball organized by the Emily Whitehead Foundation. In its inaugural year, the Believe Ball will bring together T-Cell therapy patients and their families with the doctors, scientists, researchers, and others who helped develop this therapy.
"We are honored to support the Believe Ball and the mission of the Emily Whitehead Foundation," said Michael Chambers, CEO of Aldevron. "The Foundation is an important partner in bringing breakthrough treatments, such as CAR-T, to patients. We are excited to provide assistance to the Foundation through our sponsorship of the Believe Ball. Our thoughts and prayers are with all the patients and families affected by cancer that struggle to get through each day."
"We thank Aldevron for their generous support of the 2017 Believe Ball," said Tom Whitehead, co-founder of the Emily Whitehead Foundation. "The company's dedication to advancing cancer treatments is evident from their work with the leading organizations in the field, and it is gratifying to see them go the extra mile with their direct financial contribution to the Foundation."
The inaugural 2017 Believe Ball is the Emily Whitehead Foundation's largest fundraising event to date. The event will be held on Saturday, October 28 at the Valley Forge Casino Resort in King of Prussia, Penn. Open to the public, this elegant and inspirational evening will feature a cocktail reception, seated dinner, silent auction and raffle, entertainment, and compelling stories from childhood cancer patients and their families. For more information please visit WriteABetterStory.org.
About Aldevron
Aldevron serves the biotechnology industry with custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevron-produced plasmid DNA, RNA and gene editing enzymes for research, clinical, and commercial applications. Aldevron's clients are developing revolutionary treatments in many fields including oncology, neuroscience, infectious disease and rare diseases. Company headquarters are in Fargo, N.D., with additional facilities in Madison, Wisc., and Freiburg, Germany.
About the Emily Whitehead Foundation
The Emily Whitehead Foundation is a 501(c)(3) nonprofit organization that raises awareness and funds for childhood cancer research. Emily Whitehead is a three-time cancer survivor and was the first child in the world to receive CAR-T cell therapy, a form of immunotherapy. Emily is now five years cancer-free. Since 2015, the Emily Whitehead Foundation has supported research funding to develop innovative and less toxic treatments, such as immunotherapy, for pediatric cancer patients. For more information, visit www.EmilyWhiteheadFoundation.org.
Learn more about Aldevron
PRLog ID: www.prlog.org/12672172
SOURCE Aldevron
Share this article